Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism
Open Access
- 26 December 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Brain
- Vol. 139 (2) , 317-337
Abstract
Single gene disorders of the autophagy pathway are an emerging, novel and diverse group of multisystem diseases in children. Clinically, these disorders prominently affect the central nervous system at various stages of development, leading to brain malformations, developmental delay, intellectual disability, epilepsy, movement disorders, and neurodegeneration, among others. Frequent early and severe involvement of the central nervous system puts the paediatric neurologist, neurogeneticist, and neurometabolic specialist at the forefront of recognizing and treating these rare conditions. On a molecular level, mutations in key autophagy genes map to different stages of this highly conserved pathway and thus lead to impairment in isolation membrane (or phagophore) and autophagosome formation, maturation, or autophagosome-lysosome fusion. Here we discuss ‘congenital disorders of autophagy’ as an emerging subclass of inborn errors of metabolism by using the examples of six recently identified monogenic diseases: EPG5-related Vici syndrome, beta-propeller protein-associated neurodegeneration due to mutations in WDR45, SNX14-associated autosomal-recessive cerebellar ataxia and intellectual disability syndrome, and three forms of hereditary spastic paraplegia, SPG11, SPG15 and SPG49 caused by SPG11, ZFYVE26 and TECPR2 mutations, respectively. We also highlight associations between defective autophagy and other inborn errors of metabolism such as lysosomal storage diseases and neurodevelopmental diseases associated with the mTOR pathway, which may be included in the wider spectrum of autophagy-related diseases from a pathobiological point of view. By exploring these emerging themes in disease pathogenesis and underlying pathophysiological mechanisms, we discuss how congenital disorders of autophagy inform our understanding of the importance of this fascinating cellular pathway for central nervous system biology and disease. Finally, we review the concept of modulating autophagy as a therapeutic target and argue that congenital disorders of autophagy provide a unique genetic perspective on the possibilities and challenges of pathway-specific drug development.Keywords
This publication has 217 references indexed in Scilit:
- Transcription factor EB (TFEB) is a new therapeutic target for Pompe diseaseEMBO Molecular Medicine, 2013
- Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha‐1‐anti‐trypsin deficiencyEMBO Molecular Medicine, 2013
- Differential Regulation of Distinct Vps34 Complexes by AMPK in Nutrient Stress and AutophagyCell, 2013
- Exome Sequencing Reveals De Novo WDR45 Mutations Causing a Phenotypically Distinct, X-Linked Dominant Form of NBIAThe American Journal of Human Genetics, 2012
- Mutation in TECPR2 Reveals a Role for Autophagy in Hereditary Spastic ParaparesisThe American Journal of Human Genetics, 2012
- The WD40 Repeat PtdIns(3)P-Binding Protein EPG-6 Regulates Progression of Omegasomes to AutophagosomesDevelopmental Cell, 2011
- The elimination of accumulated and aggregated proteins: A role for aggrephagy in neurodegenerationNeurobiology of Disease, 2011
- A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem CellsCell, 2010
- Disease-Specific Induced Pluripotent Stem CellsCell, 2008
- Identification of the SPG15 Gene, Encoding Spastizin, as a Frequent Cause of Complicated Autosomal-Recessive Spastic Paraplegia, Including Kjellin SyndromeThe American Journal of Human Genetics, 2008